Browse the evidence

New pharmacological molecules are likely to be treatment options for patients with rare genetic obesities in the coming years.

Practitioners should stay informed about emerging pharmacological treatments for obesity.

The positioning of new therapeutics in the management of rare genetic obesities needs to be well defined.

Clinicians should consider how to integrate new therapeutics into treatment plans for obesity.

Higher BMI was associated with a different airway shape, including larger minimum anteroposterior distance and smaller minimum lateral distance.

Understanding the changes in airway shape with BMI can help tailor OSA treatment strategies.

Meta-analysis is commonly used in sport and exercise science to synthesize empirical studies.

Practitioners should consider using meta-analysis to inform their understanding of empirical studies.

No significant difference in fatigue index for knee extensors and flexors was observed between acai supplementation and placebo.

Acai supplementation does not appear to affect fatigue levels in knee extensors and flexors post-exercise.

Polymeric biomaterials have gained tremendous interest for their potential in the prevention and treatment of obesity.

Practitioners should consider polymeric biomaterials as a promising avenue for obesity treatment.

Existing pharmaceuticals and bariatric surgeries have limited efficacy and side effects.

Awareness of the limitations of current treatments can guide practitioners in exploring new options.

Loss-of-function mutations in the genes encoding POMC, MC3R, and MC4R can lead to early-onset obesity and developmental dysregulation.

Understanding these mutations can inform treatment strategies for obesity.

Recent studies have identified new genetic regulatory mechanisms and potential biomarker regions for the POMC gene and MC4R secondary messenger pathway associated with obesity.

These findings may lead to new diagnostic tools for obesity.

1,260,969 (8.5%) Black people and 4,989,919 (4.7%) non-Black people had ≥CKD stage 3 according to the 2021 CKD-EPI formula.

Practitioners should consider the impact of the new eGFR formula on the classification of CKD in patients when prescribing antiobesity medications.

Obesity affects around 40% of adults in the United States.

Health practitioners should be aware of the high prevalence of obesity in the adult population.

Obesity accounts for $172.74 billion in annual expenditures in the United States.

Understanding the economic burden of obesity can inform healthcare policy and resource allocation.

Obesity alone did not emerge as a robust predictor of major adverse cardiovascular events (MACEs).

Obesity should not be solely relied upon as a risk factor in cardiovascular assessments.

Estradiol levels were not associated with cognitive function in either sex.

Practitioners should note that estradiol does not appear to influence cognitive function in this population.

Total testosterone levels were not associated with cognitive function in women.

Practitioners should be aware that testosterone does not influence cognitive function in women with T2DM.

A better understanding of antidiabetic drugs' effects on skeletal muscle lipid metabolism is needed.

Future research should prioritize understanding how antidiabetic drugs affect lipid metabolism in skeletal muscle.

The compounds K2 and K5 modify CCK1 activity by preventing/hindering interactions between CCK peptides and CCK1.

Understanding how K2 and K5 interact with CCK1 can guide drug development.

Obesogenic stimuli promote adipose tissue macrophages to recruit neutrophils from the bone marrow in mice.

Understanding neutrophil recruitment can inform strategies to manage inflammation in obesity.

Inhibiting neutrophil recruitment out of the bone marrow in obese mice or during weight loss reduces bone marrow myelopoiesis and adipose tissue inflammation.

Targeting neutrophil recruitment may help reduce inflammation during obesity management.

In humans with obesity, plasma neutrophil chemokines are increased and correlate with increased insulin resistance, but do not decrease with weight loss.

Monitoring neutrophil chemokines may provide insights into insulin resistance in obese patients.

Nitro-oleic acid (NO2-OA) treatment improves glucose tolerance in high fat diet (HFD)-fed Nrf2fl/fl mice but does not improve glucose tolerance in adipocyte-specific Nrf2 knockout (ANKO) mice.

NO2-OA may be effective for improving glucose tolerance in certain populations but not in those lacking Nrf2 in adipocytes.

Adipocyte-specific deletion of Nrf2 negates the protective effects of nitro-oleic acid on glucose tolerance.

Understanding the role of Nrf2 in adipocytes can inform strategies for managing glucose tolerance in obesity.

Nitro-oleic acid treatment does not alter body weight in Nrf2fl/fl and ANKO mice on both high fat diet (HFD) and low-fat diet (LFD).

NO2-OA may not affect body weight, suggesting its effects are more focused on metabolic parameters rather than weight loss.

Section 1115 Demonstration Waivers are currently serving as a temporary funding mechanism for nutrition-related programs.

Understanding the temporary nature of current funding can inform program planning.